NCIt definition : A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential
antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell
surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent
cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against
CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell
surface phosphoprotein that is exclusively expressed on B cells during most stages
of B cell development and is often overexpressed in B-cell malignancies. Ublituximab
has a specific glycosylation profile, with a low fucose content, that may enhance
its ADCC response against malignant B cells.;